Antidepressant Drugs Market, By Class (Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants and Others), By Application (Major Depressive Disorder, Obsessive-compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others), By Region - Global Analysis Forecast Till 2030

The market for antidepressant drugs surpassed USD 14.1 billion in 2021 and is predicted to grow at a CAGR of more than 10.1% between 2022 and 2030.

Depression is a group of mental health issues characterized by a lack of positive emotion, a low mood, and various cognitive, physical, emotional, and behavioral symptoms. It is a prevalent disease that affects one out of every five Americans. Various factors, including genetics, stress, and brain chemistry, cause depression.

The Antidepressant Drugs market is being driven by an increase in the prevalence of depression, an increase in the geriatric population, and advancements in R&D activities in the pharmaceutical industry to develop innovative drugs. Furthermore, rising awareness of depression, an increase in the number of clinical trials, and an increase in the number of people suffering from stress all contribute to the growth of the antidepressant drug market. Furthermore, the growing geriatric population drives the antidepressant drugs market growth.

Antidepressant therapy is commonly prescribed for individuals struggling with depression, but it's essential to be aware of potential side effects. While these medications can be effective in alleviating depressive symptoms, they may also present certain adverse effects. Patients should be cautious about antidepressant overdose, as it can have severe consequences. Determining the appropriate antidepressant dosage is crucial, as it ensures optimal effectiveness while minimizing side effects. Monitoring response rates to antidepressant treatment is necessary to gauge its efficacy and make any necessary adjustments. Additionally, understanding the mechanisms of action behind antidepressants helps clinicians tailor treatment plans for individual patients. When discontinuing antidepressants, patients may experience withdrawal symptoms, known as antidepressant discontinuation syndrome. Overall, following antidepressant treatment guidelines and considering the safety profile of these medications contributes to better mental health outcomes.

Market Dynamics

Drivers:

• Rising Rates of Depression

According to the National Institute of Mental Health, approximately 17.3 million people in the United States experienced major depressive episodes in 2017. (NIMH). Adults aged 18 to 25 years have a higher incidence rate. As a result, with high-stress levels due to various socioeconomic factors and significant spending power within this range, the segment is expected to grow rapidly during the forecast period.

• Technological Development

Increased technological development in the pharmaceutical industry to produce advanced tricyclic antidepressant drugs is expected to boost revenue opportunities for the global antidepressant drugs market during the forecast period 2022-2029. Furthermore, the presence of key manufacturing companies developing antidepressant drugs enables Antidepressant Drugs market growth.

Restraints:

• Increased side effects

Several side effects of antidepressant use, such as feeling agitated, shaky, or anxious, indigestion and stomach aches, diarrhea or constipation, and loss of appetite, may limit the global antidepressant drugs market growth over the forecast period.

• High Cost

The high cost of developing antidepressants will limit request growth.

This global antidepressants request report contains information on new recent developments, trade regulations, import-export analysis,  product analysis, value chain optimization,  request share, the impact of domestic and localized request players,  openings in terms of arising profit pockets, changes in request regulations, strategic request growth analysis,  request size,  order request growths,  operation niches and dominance, product blessings, product launches, and so on.

Key players:

• Mallinckrodt  

• Sun Pharmaceutical Industries Ltd.  

• Novartis AG  

• Endo Pharmaceuticals plc

• Zydus Cadila  

• Mylan N.V.  

• Mayne Pharma Group Limited  

• Teva Pharmaceutical Industries Ltd  

• Amneal Pharmaceutical Inc  

• Avet Pharmaceuticals Inc.  

• Aurobindo Pharma

• WOCKHARDT  

• Currax Pharmaceuticals LLC

Market Segmentation:

Antidepressant Drugs Market, By Drug class

• Selective Serotonin Reuptake Inhibitors (SSRIs)

• Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

• Tricyclic Antidepressants

• Others

Antidepressant Drugs Market, By Application

• Major Depressive Disorder

• Obsessive-compulsive Disorder

• Generalized Anxiety Disorder

• Panic Disorder

• Others

Antidepressant Drugs Market, By region

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Turkey

  • Sweden

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • New Zealand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

Regional Analysis:

The North American Antidepressant Drugs market is expected to grow significantly, owing to key market players focusing on inorganic strategies such as partnerships to research treatment-resistant depression and its treatment. For example, in March 2021, Novamind, a mental health company, announced that Merck & Co. had chosen its wholly-owned subsidiary, Cedar Clinical Research, as a key research site for a clinical trial focused on treatment-resistant depression. The phase II study would look at the efficacy and safety of MK-1942, a new Merck drug for treatment-resistant depression (TRD).

Scope of the Report:

User

Tab Content